Abstract 4501
Background
Nowadays breast cancer (BC) may have high cure rate, so is important how to prevent or resolve adjuvant treatments adverse effects. AI are an essential treatment in patients with early diagnosed estrogen-dependent BC. Our aim is to analyse bone mass loss in BC, focussing on fractures incidence and their risk as well as preventive methods. The latest consensus establishes as intervention criteria a BMD value> -2T Score and 2 or more risk factors.
Methods
114 BC patients and 272 without BC sent to our centre in 2010 to perform densitometry (DXA) were included in our review. Beyond DXA and anthropometry we carried out an extensive clinical questionnaire on co-morbidity, risk factors for osteoporosis, medication, personal and relatives history of fractures. Hospital and primary care records were reviewed in BC patients until May 2017 to determine fractures incidence.
Results
There were significant differences in age (BC 59 ± 11 vs 62 ± 11 years, p = 0.01). No differences in weight, height, menarche/menopause or toxic habits. 25% had personal history of fracture (31% control p = 0.05) and 17% relatives history (27% control p = 0.03). 4.3% of corticosteroid intake (16% control p = 0.01). There were no differences in T Lumbar Score (0.97 ± 1.3 vs -0.94 ± -1.2) or in femur neck (-.0.93 ± 1.2 vs-1.1 ± 1) but yes in the fracture risk assessment tool (FRAX) for major fractures with BMDM (BC 7 ± 5% vs 11 ± 6% p0.02) and hip fractures (1.2 ± 2 vs 2.4 ± 4 p 0.02). Patients with AI lost bone mass at two years (BMD 0.96 ± 1.87 to 0.921 ± 0.18 g / cm2 p0.03), without changes in control group. At 7 years follow-up, 8 fractures appeared in patients with AI (3 Colles, 3 vertebral and 2 humerus), 4 patients with Exemestane (E), 2 with Letrozole (L) and 2 with Anastrozole (A) (40% took E, 26% A and 20% L). Only 3 of the 8 had baseline T Lumbar Score <-2. 7% BC patients received antiresorptives and 9% vitamin D.
Conclusions
There were more fractures and bone mass loss in BC pacients treated with AI in our sample. Despite the small sample size, it is striking that, patients with BC would not meet the indication of preventive treatment according to the latest recommendations, since only 30% of the patients would be covered. It could be considered to associate other diagnostic measures to treat patients with greater risk of fracture (FRAX).
Clinical trial identification
Legal entity responsible for the study
Central Univesity Hospital of Asturias.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract